Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (9): 11-16.doi: 10.6040/j.issn.1671-7554.0.2018.251

Previous Articles    

Combinatorial anti-PD-1 and endostatin therapeutic efficacy in Lewis lung cancer mice

JIANG Yunfeng, DONG Xiaopeng, ZHAO Xiaogang   

  1. Department of Thoracic Surgery, the Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Published:2022-09-27

PDF (PC)

77

Abstract: Objective To explore the antitumor effect of anti-PD-1 combined with angioendostatin on lung cancer in Lewis mice. Methods Lewis lung cancer C57BL/6 mice models were constructed and randomly divided into 4 groups: group A(PBS control), group B(anti-PD-1), group C(endostatin)and group D(anti-PD-1 combined with endostatin). The tumor volume was measured. The content of INFγ in the plasma was detected with ELISA, and the CD31 and VEGF contents were determined with immunohistochemistry. Results Compared with group A, group B and D had significantly inhibited tumor growth(P<0.001); group C had reduced tumor size but there was no statistical difference(P=0.084). Compared with group A, groups D, C and B had significantly elevated INFγ concentration(P<0.001), and group D showed the most obvious increase. Compared with group A, group D had significantly lower positive expression of VEGF(P<0.001). MVD count decreased significantly in group D compared with that in group A(P<0.001), group D compared with group B(P=0.019), and group D compared with group C(P<0.001). Conclusion Anti-PD-1 combined with endostatin can significantly slow down the tumor growth, effectively improve the tumor microenvironment, and play a synergistic antitumor effect.

Key words: Lung cancer, Programmed cell death-1, Endostatin, Tumor microenvironment

CLC Number: 

  • R734.2
[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930.
[3] Zheng YW, Li RM, Zhang XW, et al. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome[J]. Cancer Invest, 2013, 31(3): 197-205.
[4] Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186.
[5] O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 88(2): 277-285.
[6] Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy[J]. Angiogenesis, 2017, 20(2): 185-204.
[7] Liang J, Liu X, Xie Q, et al. Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma[J]. Chin J Cancer Res, 2016, 28(4): 452-460.
[8] Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia[J]. Nature, 1989, 339(6219): 58-61.
[9] Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Exp Cell Res, 2006, 312(5): 594-607.
[10] Zhao X, Su Y, You J, et al. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA(N2)non-small cell lung cancer without increasing adverse effects[J]. Oncotarget, 2016, 7(38): 62619-62626.
[11] Gampenrieder SP, Westphal T, Greil R. Antiangiogenic therapy in breast cancer[J]. Memo, 2017, 10(4): 194-201.
[12] Yao S, Zhu Y, Chen L. Advances in targeting cell surface signaling molecules for immune modulation[J]. Nat Rev Drug Discov, 2013, 12(2): 130-146.
[13] Siwiec A, Majdan M. The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus[J]. Postepy Hig Med Dosw(Online), 2015, 69: 534-542. doi:10.5604/17322693.1150784.
[14] Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 2010, 28(19): 3167-3175.
[15] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454.
[16] Qian N, Gao L, Dong L, et al. Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein(P-V)[J]. Protein Expr Purif, 2015, 109: 1-6. doi:10.1016/j.pep.2015.01.004.
[17] Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade[J]. Sci Transl Med, 2017, 12, 9(385). doi:10.1126/scitranslmed.aak9670.
[18] Yasuda S, Sho M, Yamato I, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2(VEGFR2)induces synergistic anti-tumour effect in vivo[J]. Clin Exp Immunol, 2013, 172(3): 500-506.
[19] Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy[J]. Science, 2005,307(5706): 58-62.
[20] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med, 2013, 19(11): 1423-1437.
[21] Gunaje JJ, Bahrami AJ, Schwartz SM, et al. PDGF-dependent regulation of G protein signaling-5 expression and vascular smooth muscle cell functionality[J]. Am J Physiol Cell Physiol, 2011, 301(2): C478-489.
[22] 何朗, 孙永红, 蒋莉, 等. rh-Endostatin与肿瘤血管正常化时相的关系初探[J]. 中华肿瘤防治杂志, 2016, 23(19): 1291-1296. HE Lang, SUN Yonghong, JIANG Li, et al. Preliminary research of the relationship between rh-Endostatin and micro-vascular normalization course[J]. Chin J Cancer Prevention Treatment, 2016, 23(19): 1291-1296.
[23] Peng Q, Li M, Wang Z, et al. Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin[J]. Thorac Cancer, 2013, 4(3): 295-305.
[24] Ishikawa H, Nakao K, Matsumoto K, et al. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene[J]. Hepatology, 2003, 37(3): 696-704.
[1] HAN Jing, JIA Chunling. Effects of periodontal basic therapy on postoperative pneumonia in patients with lung cancer before thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 113-118.
[2] GAO Zhongxia, ZHANG Ming, FAN Mingde, TAN Chenyang, WANG Mengdi, WANG Chao, FAN Yuefei, DING Shouluan, WANG Chengwei. Efficacy and prognostic factors of gamma knife in treating 81 cases of brain metastases from lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 44-49.
[3] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[4] WANG Fuli, SUN Yinping, QIN Jie, RONG Jiansheng. Efficacy of DC-CIK cells combined with EGFR-TKI for 35 elderly patients with advanced EGFR-mutant lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 110-117.
[5] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[6] Jinming YU,Weiwei YAN,Dawei CHEN. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[7] PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28.
[8] ZHANG Yu, TANG Xing, MA Haitao, JIANG Wei. Value of indocyanine green fluorescence in thoracoscopic segmentectomy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 38-42.
[9] ZHANG Xiqin, ZHU Shouhui, LIU Ning, WANG Yu, CHEN Jiazhen, HU Xudong. Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 43-46.
[10] LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.
[11] SHI Shuyuan, GUAN Zhiyu, SUN Daqiang. Recombinant human vascular endostatin enhances antitumour activity of EGFR-TKIs for lung cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 6-10.
[12] LI Xingkai, LIU Zhanye, JIANG Yunfeng, LI Jun. Clinicopathological factors and prognosis between primary central and peripheral lung squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 73-78.
[13] ZHANG Xinke, CHEN Hongyuan, YANG Ying, LI Yan, WANG Fengshan. Development and evaluation of chitosan gene nanoparticles loaded with recombinant plasmid pVAX1/Tat PTD-endostatin [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 43-48.
[14] ZENG Haiyan, LI Rui, SUN Xindong, XIE Peng, MENG Xue, FAN Bingjie, LI Wanlong, YUAN Shuanghu. Association analysis of brain metastases after prophylactic cranial irradiation in local disease small cell lung cancer: a bicenter study [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 61-66.
[15] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd